IFM Therapeutics Inc. closed a $27 million series A financing led by Atlas Venture and Abingworth, with participation from Novartis AG. The Cambridge, Mass.-based company, incubated at Atlas, will use the financing to advance and expand its early stage portfolio of preclinical small-molecule modulators.